Krsnaa Diagnostics , one of India's largest integrated diagnostic service providers, has outlined an ambitious growth strategy focusing on expansion and technological integration to drive revenue growth exceeding 20%.

Expansion Plans

The company plans to significantly expand its footprint across India, with a target of adding over 200 centers in the next two years. This expansion is expected to strengthen Krsnaa's presence in both public and private healthcare sectors.

Technological Advancements

Krsnaa Diagnostics is placing a strong emphasis on scaling its radiology and pathology verticals through automation and artificial intelligence (AI) integration. This technological push aims to enhance efficiency and improve diagnostic accuracy.

Business Model and Partnerships

The company is pursuing an asset-light growth model while focusing on strengthening its business-to-government relationships. This approach is expected to provide margin stability and support sustainable growth.

Financial Performance

According to the company's latest financial results:

The company achieved its highest-ever quarterly profit, with PAT increasing by 22% year-on-year to ₹239.00 million. EBITDA margins improved to 29%, reflecting strong operating leverage.

Operational Highlights

• Krsnaa served approximately 5.4 million patients in Q2 FY2026.
• The company's network includes 186 CT/MRI centers and 120 pathology labs across 18 states and union territories.
• Krsnaa has served over 75 million patients since its inception.

Quality Accreditations

Krsnaa Diagnostics has received several notable accreditations:

• First company in India to receive American College of Radiology (ACR) accreditation
• First NABH accredited tele-radiology hub in India
• 57 NABL accredited pathology labs
• 36 NABH accredited radiology centers

Future Outlook

With its expansion plans and focus on technological integration, Krsnaa Diagnostics aims to cement its position as one of Asia's largest radiology players. The company's ongoing Rajasthan project is expected to significantly expand its pathology network, making it one of India's most accessible diagnostic service providers.

As Krsnaa Diagnostics continues to execute its growth strategy, investors and industry observers will be watching closely to see if the company can achieve its projected revenue growth and maintain its strong financial performance in the coming quarters.

Krsnaa Diagnostics Limited (NSE: KRSNAA) has reported a strong financial performance for the second quarter of the fiscal year 2025-26, showcasing significant growth across key metrics.

Financial Highlights

The company's consolidated financial results for Q2 FY2025-26 reveal year-over-year improvements:

Revenue Growth and Operational Performance

Krsnaa Diagnostics witnessed a 10.5% year-over-year increase in revenue from operations, reaching 2,059.91 million rupees in Q2 FY2025-26.

Profitability Improvements

The company's financial results show:

• EBITDA grew by 19.9% to 592.39 million rupees.
• Net profit increased by 22.2%, reaching 239.45 million rupees.
• The EBITDA margin expanded by 222 basis points to 28.74%.

Balance Sheet and Cash Flow

As of September 30, 2025, Krsnaa Diagnostics reported:

• Total assets of 15,066.91 million rupees
• Total equity of 9,229.55 million rupees
• Cash and cash equivalents of 105.60 million rupees

The company's cash flow from operating activities for the half-year ended September 30, 2025, stood at 518.74 million rupees.

Outlook

The diagnostic services sector in India continues to show growth potential. Krsnaa Diagnostics' performance in Q2 FY2025-26 reflects positively on its position in the market.

Note: This article is based on the consolidated financial results of Krsnaa Diagnostics Limited for the quarter ended September 30, 2025. Investors are advised to review the full financial statements and consult with financial advisors before making investment decisions.